RGEN
REPLIGEN CORP
NASDAQ · Healthcare · Medical - Instruments & Supplies · US
$180.17
+1.83%0
Insider buys (3m)
6
Insider sells (3m)
-$4.4M
Net value (3m)
+33.2%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Oct 8, 2026 | Douglass Brian Robb · officer: CHIEF PRODUCT OFFICER | A-Award | 675 | $175 |
| Oct 8, 2026 | Douglass Brian Robb · officer: CHIEF PRODUCT OFFICER | A-Award | 700 | $0.00 |
| Oct 6, 2026 | Loeillot Olivier · director, officer: Chief Executive Officer | M-Exempt | 4,202 | $155 |
| Oct 6, 2026 | Loeillot Olivier · director, officer: Chief Executive Officer | Sale | 4,202 | $190 |
| Oct 6, 2026 | Loeillot Olivier · director, officer: Chief Executive Officer | Sale | 1,333 | $179 |
| Oct 5, 2026 | Loeillot Olivier · director, officer: Chief Executive Officer | F-InKind | 1,248 | $182 |
| Sep 28, 2026 | Garland Jason K · officer: CFO | F-InKind | 421 | $190 |
| Sep 25, 2026 | Loeillot Olivier · director, officer: Chief Executive Officer | Sale | 4,542 | $190 |
| Sep 25, 2026 | Loeillot Olivier · director, officer: Chief Executive Officer | M-Exempt | 4,542 | $155 |
| Sep 25, 2026 | Loeillot Olivier · director, officer: Chief Executive Officer | M-Exempt | 8,404 | $155 |
| Sep 22, 2026 | Loeillot Olivier · director, officer: Chief Executive Officer | M-Exempt | 5,426 | $142 |
| Sep 22, 2026 | Loeillot Olivier · director, officer: Chief Executive Officer | Sale | 5,426 | $180 |
| Sep 8, 2026 | Loeillot Olivier · director, officer: Chief Executive Officer | Sale | 3,035 | $166 |
| Sep 8, 2026 | Loeillot Olivier · director, officer: Chief Executive Officer | F-InKind | 2,842 | $170 |
| Sep 2, 2026 | Hughes Violetta · officer: CHIEF ACCOUNTING OFFICER | A-Award | 2,466 | $0.00 |
| Sep 2, 2026 | Hughes Violetta · officer: CHIEF ACCOUNTING OFFICER | F-InKind | 277 | $170 |
| Aug 21, 2026 | Loeillot Olivier · director, officer: Chief Executive Officer | Sale | 5,426 | $180 |
| Aug 21, 2026 | Loeillot Olivier · director, officer: Chief Executive Officer | M-Exempt | 5,426 | $142 |
| Jul 17, 2026 | Garland Jason K · officer: CFO | Sale | 530 | $150 |
| Jun 26, 2026 | Garland Jason K · officer: CFO | Sale | 733 | $145 |
| May 18, 2026 | EGLINTON MANNER CARRIE · director | A-Award | 2,239 | $103 |
| May 18, 2026 | BARTHELEMY NICOLAS · director | A-Award | 2,239 | $103 |
| May 18, 2026 | MUIR GLENN P · director | A-Award | 995 | $0.00 |
| May 18, 2026 | MUIR GLENN P · director | A-Award | 2,239 | $103 |
| May 18, 2026 | DAWES KAREN A · director | A-Award | 995 | $0.00 |
| May 18, 2026 | Pax Margaret · director | A-Award | 2,239 | $103 |
| May 18, 2026 | BARTHELEMY NICOLAS · director | A-Award | 995 | $0.00 |
| May 18, 2026 | Pax Margaret · director | A-Award | 995 | $0.00 |
| May 18, 2026 | EGLINTON MANNER CARRIE · director | A-Award | 995 | $0.00 |
| May 18, 2026 | Mhatre Rohin · director | A-Award | 995 | $0.00 |
Institutional positioning
13F filings over the trailing two quarters
New 177Increased 357Reduced 277Sold out 58
| Filer | Action | Shares | Filed |
|---|---|---|---|
| BLACKROCK, INC. | Reduced | 5,993,054 | May 13, 2026 |
| BlackRock, Inc. | Reduced | 5,384,938 | Aug 7, 2026 |
| PRICE T ROWE ASSOCIATES INC /MD/ | Increased | 4,878,141 | May 15, 2026 |
| FMR LLC | Increased | 3,326,690 | Aug 13, 2026 |
| FMR LLC | Increased | 2,886,786 | May 15, 2026 |
| UNITED CAPITAL FINANCIAL ADVISORS, LLC | Increased | 2,790,650 | Aug 17, 2026 |
| UNITED CAPITAL FINANCIAL ADVISERS, LLC | Increased | 2,773,980 | May 15, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | Increased | 2,411,171 | Aug 13, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | New Position | 2,396,511 | May 15, 2026 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | Increased | 2,312,825 | Aug 13, 2026 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | New Position | 2,305,094 | May 8, 2026 |
| MAVERICK CAPITAL LTD | Increased | 1,984,554 | Aug 14, 2026 |
| STATE STREET CORP | Increased | 1,800,530 | Sep 22, 2026 |
| STATE STREET CORP | Increased | 1,777,285 | May 15, 2026 |
| PRICE T ROWE ASSOCIATES INC /MD/ | Reduced | 1,752,274 | Aug 14, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Oct 8, 2026